ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 421

Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity

Nathan den Broeder1, Lieke Tweehuysen1, Noortje van Herwaarden1, Thomas Vogl2, F.H.J. van den Hoogen1, Rogier Thurlings3 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2University of Muenster, Muenster, Germany, 3Rheumatology, Radboudumc, Nijmegen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, biomarkers and rheumatoid arthritis (RA), Clinical Response

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To date, no predictors for successful dose reduction or discontinuation have been identified.2 Calprotectin (a heterodimer of S100A8/S100A9) might be a promising biomarker in this context.3,4

 

Objectives: To investigate the predictive value of baseline serum calprotectin for successful TNFi dose reduction or discontinuation in RA patients with low disease activity.

 

Methods: Data was derived from the intervention arm of the DRESS (Dose REduction Strategies of Subcutaneous TNFi) study, which showed non-inferiority of a dose reduction strategy of adalimumab or etanercept compared to usual care.1 TNFi dose interval was reduced stepwise every 3 months until flare (DAS28-CRP increase >1.2 or >0.6 if current DAS28-CRP ≥3.2) or discontinuation. Patients were classified at 18 months as being successfully dose reduced, discontinued or not able to reduce the TNFi dose. At baseline, quantification of calprotectin was carried out on serum samples using ELISA. Calprotectin levels were compared between each group and receiver-operator-characteristic (ROC) curves were created. In addition, calprotectin was correlated cross-sectionally with several clinical markers for disease activity.

 

Results: Calprotectin levels were available from 102 of 121 patients randomised to the intervention group; 61% were women, 63% received etanercept and 37% received adalimumab. Overall, 46% of patients successfully reduced the TNFi dose, 19% of patients successfully discontinued TNFi and 35% of patients could not reduce the TNFi dose. In these groups, median calprotectin levels were 599 ng/ml  (p25-p75: 473-965), 629 ng/mL (p25-p75: 453-896) and 624 ng/mL (p25-p75: 514-931) (p=0.801) (Figure 1). The area under the ROC-curve was 0.52 (95% CI: 0.40-0.63)  for predicting successful TNFi dose reduction, 0.53 (95% CI: 0.38-0.67)  for successful TNFi discontinuation and 0.54 (95% CI: 0.42-0.66) for no dose reduction possible. Calprotectin levels were weakly correlated with C-reactive protein (CRP) levels with a Spearman ρ of 0.21 (p=0.03). No significant correlation was found between calprotectin and age, gender, DAS28-CRP, rheumatoid factor or ACPA positivity.

 

Conclusion: Serum calprotectin is not predictive for successful TNFi dose reduction or discontinuation in RA patients with low disease activity, and calprotectin was only weakly correlated to CRP levels. These results might be caused by the lack of variability in calprotectin levels at baseline as all patients were in low disease activity state.

Figure 1 Calprotectin levels per outcome

References:

1 van Herwaarden et al. BMJ 2015;350:h1389

2 Tweehuysen et al. Arthritis Rheumatol 2017;69(2):301-308

3 Hammer et al. Ann Rheum Dis 2010;69(1):150-4

4 Choi et al. Ann Rheum Dis 2015;74(3):499-505

 


Disclosure: N. den Broeder, None; L. Tweehuysen, None; N. van Herwaarden, None; T. Vogl, None; F. H. J. van den Hoogen, Biogen Idec, 5,Celltrion, 5,Janssen Pharmaceutica Product, L.P., 5,Mundipharma, 5,Sandoz, 5; R. Thurlings, None; A. A. Den Broeder, None.

To cite this abstract in AMA style:

den Broeder N, Tweehuysen L, van Herwaarden N, Vogl T, van den Hoogen FHJ, Thurlings R, Den Broeder AA. Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-calprotectin-is-not-predictive-for-successful-dose-reduction-or-discontinuation-of-tnf-inhibitors-in-ra-patients-with-low-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-calprotectin-is-not-predictive-for-successful-dose-reduction-or-discontinuation-of-tnf-inhibitors-in-ra-patients-with-low-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology